|
Maya's Biotech Briefing
Biotech panel with John Maraganore and Jeremy Levin, MoonLake’s disputed autoimmune data release, and the added purification complexity of bispecific antibodies.
The top 10 stories from Tue Aug 11, 2026 07:04 AM to Wed Aug 12, 2026 07:00 AM
Generated August 12, 2026 at 7:00 AM
|
|
|
#1 Does China Reimburse Its Most Innovative Drugs? Published 2026-08-12 China’s basic medical insurance covers some of the country’s most innovative drugs, with solid tumors as the leading indication and Chinese companies dominating the covered products. Covered by: insights.citeline.com |
#2 New Drug Application for LAE002 (afuresertib) Accepted by China's National Medical Products Administration Published 2026-08-12 Laekna (2105.HK) said China’s NMPA CDE accepted its NDA for LAE002 (afuresertib) for treating patients, with details of the indication not provided in the available text. Covered by: prnewswire.com |
#3 July FDA approvals deliver first products for three biotechs Published 2026-08-11 In July, the FDA approved six novel drugs, including the first oral PCSK9 inhibitor, delivering initial products for three biotech companies. Covered by: biocentury.com |
#4 Bispecific Antibody Purification’s Complexity Problem and How to Fix It Published 2026-08-11 A webinar highlighted that bispecific antibodies produce more product variants and may be less compatible with protein A chromatography, requiring analytics-guided affinity and non-affinity purification optimization. Covered by: genengnews.com |
#5 Vedanta Biosciences Nabs $60M Financing Round Published 2026-08-11 Vedanta Biosciences, based in Cambridge, Massachusetts, secured $60 million in funding. Covered by: vcnewsdaily.com |
#6 STAT+: Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate? Published 2026-08-11 MoonLake Immunotherapeutics reported “positive” results for an autoimmune drug candidate, but the article alleges the data release is unclear and repeatedly problematic. Covered by: statnews.com |
#7 Cost neutrality of BLC versus WLC in a real-world setting demonstrated by new OPTUM study in the U.S. Published 2026-08-11 Photocure ASA says a new U.S. OPTUM retrospective study found healthcare resource utilization and costs for blue light versus white light cystoscopy in non-muscle-invasive bladder cancer were cost-neutral. Covered by: prnewswire.com, prnewswire.com |
#8 With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development Published 2026-08-12 The article claims AI is increasingly used in drug development, including in pharma R&D and investment markets, to accelerate and reshape how new drugs are developed. Covered by: biospace.com |
#9 The State of Biotech 2026 Published 2026-08-11 The State of Biotech 2026 panel features John Maraganore of City Therapeutics and Jeremy Levin of Ovid Therapeutics, both with long leadership roles in RNAi and epilepsy drug development. Covered by: genengnews.com |
#10 Silence causes uproar in rare blood cancer space as data sets high bar for competitors Published 2026-08-11 Silence Therapeutics reported mid-stage trial success for its siRNA drug in polycythemia vera, raising expectations for similar therapies from Takeda, Agios, and Disc Medicine. Covered by: biospace.com |
